TERNS PHARMACEUTICALS INC's ticker is TERN and the CUSIP is 880881107. A total of 104 filers reported holding TERNS PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $59,417 | +1363.1% | 8,725 | +1309.5% | 0.00% | – |
| Q1 2024 | $4,061 | -97.3% | 619 | -97.3% | 0.00% | -100.0% |
| Q4 2023 | $149,244 | +2714.9% | 22,996 | +2081.8% | 0.00% | – |
| Q3 2023 | $5,302 | -92.4% | 1,054 | -86.8% | 0.00% | -100.0% |
| Q2 2023 | $70,097 | +162916.3% | 8,011 | +119.5% | 0.00% | +100.0% |
| Q1 2023 | $43 | -24.6% | 3,650 | -34.1% | 0.00% | -50.0% |
| Q4 2022 | $57 | -99.9% | 5,539 | -16.1% | 0.00% | +100.0% |
| Q3 2022 | $39,000 | +50.0% | 6,601 | -37.0% | 0.00% | 0.0% |
| Q2 2022 | $26,000 | +136.4% | 10,480 | +194.7% | 0.00% | – |
| Q1 2022 | $11,000 | 0.0% | 3,556 | +130.5% | 0.00% | – |
| Q4 2021 | $11,000 | +37.5% | 1,543 | +103.3% | 0.00% | – |
| Q3 2021 | $8,000 | -42.9% | 759 | -35.7% | 0.00% | – |
| Q2 2021 | $14,000 | 0.0% | 1,180 | +92.2% | 0.00% | – |
| Q1 2021 | $14,000 | – | 614 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUPERSTRING CAPITAL MANAGEMENT LP | 956,542 | $6,514,051 | 8.21% |
| Vivo Capital, LLC | 6,182,992 | $42,106,176 | 3.89% |
| Soleus Capital Management, L.P. | 4,947,738 | $33,694,096 | 2.97% |
| ACUTA CAPITAL PARTNERS, LLC | 369,280 | $2,514,797 | 2.12% |
| GREAT POINT PARTNERS LLC | 1,149,406 | $7,827,455 | 1.50% |
| VR Adviser, LLC | 3,410,058 | $23,222,495 | 1.48% |
| Octagon Capital Advisors LP | 1,364,400 | $9,291,564 | 1.46% |
| Deep Track Capital, LP | 6,100,000 | $41,541,000 | 1.24% |
| Orbimed Advisors | 7,619,135 | $51,886,309 | 1.02% |
| Worth Venture Partners, LLC | 17,470 | $118,971 | 0.88% |